Eisuke Kurihara

420 total citations
12 papers, 271 citations indexed

About

Eisuke Kurihara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Eisuke Kurihara has authored 12 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Eisuke Kurihara's work include Lung Cancer Treatments and Mutations (5 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Cancer Mechanisms and Therapy (2 papers). Eisuke Kurihara is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Cancer Mechanisms and Therapy (2 papers). Eisuke Kurihara collaborates with scholars based in Japan and Canada. Eisuke Kurihara's co-authors include Shuta Tomida, Yuta Takahashi, Junichi Soh, Hiromasa Yamamoto, Kazuhiko Shien, Kei Namba, Shinichi Toyooka, Hiroki Sato, Takahiro Yoshioka and Hidejiro Torigoe and has published in prestigious journals such as BMC Cancer, Cancer Science and Molecular Cancer Research.

In The Last Decade

Eisuke Kurihara

10 papers receiving 270 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eisuke Kurihara Japan 8 148 113 110 48 38 12 271
Dario Nicolella Italy 9 227 1.5× 158 1.4× 108 1.0× 45 0.9× 33 0.9× 16 332
Laura Demurtas Italy 10 235 1.6× 87 0.8× 112 1.0× 80 1.7× 26 0.7× 20 363
Cristina Aguayo Spain 7 167 1.1× 85 0.8× 85 0.8× 72 1.5× 42 1.1× 17 301
Jesper Andreas Palshof Denmark 9 246 1.7× 134 1.2× 99 0.9× 49 1.0× 35 0.9× 16 361
G. Atalay Belgium 7 182 1.2× 72 0.6× 63 0.6× 82 1.7× 40 1.1× 12 317
Tae‐You Kim South Korea 9 194 1.3× 121 1.1× 182 1.7× 82 1.7× 40 1.1× 10 402
Yiming Zhao China 10 131 0.9× 72 0.6× 122 1.1× 64 1.3× 16 0.4× 19 293
P. Marpicati Italy 10 214 1.4× 104 0.9× 56 0.5× 73 1.5× 21 0.6× 36 323
James D. Peyton United States 10 200 1.4× 145 1.3× 175 1.6× 53 1.1× 17 0.4× 27 363
Lihou Dong China 9 163 1.1× 56 0.5× 86 0.8× 34 0.7× 15 0.4× 19 294

Countries citing papers authored by Eisuke Kurihara

Since Specialization
Citations

This map shows the geographic impact of Eisuke Kurihara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eisuke Kurihara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eisuke Kurihara more than expected).

Fields of papers citing papers by Eisuke Kurihara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eisuke Kurihara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eisuke Kurihara. The network helps show where Eisuke Kurihara may publish in the future.

Co-authorship network of co-authors of Eisuke Kurihara

This figure shows the co-authorship network connecting the top 25 collaborators of Eisuke Kurihara. A scholar is included among the top collaborators of Eisuke Kurihara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eisuke Kurihara. Eisuke Kurihara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
2.
Kurihara, Eisuke, et al.. (2023). [Resection of Chest Wall Metastasis from Rectal Mucinous Carcinoma-A Case Report].. PubMed. 50(10). 1085–1087.
3.
Shien, Kazuhiko, Kota Araki, Akihiro Miura, et al.. (2020). Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation. Anticancer Research. 40(5). 2667–2673. 7 indexed citations
4.
Kurihara, Eisuke, Kazuhiko Shien, Hidejiro Torigoe, et al.. (2019). Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. Anticancer Research. 39(4). 1767–1775. 8 indexed citations
5.
Yoshioka, Takahiro, Kazuhiko Shien, Yuta Takahashi, et al.. (2019). Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells. Cancer Science. 110(8). 2549–2557. 30 indexed citations
7.
Shien, Kazuhiko, Takahiro Yoshioka, Hidejiro Torigoe, et al.. (2019). Anti‑tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations. Oncology Letters. 17(3). 2729–2736. 20 indexed citations
8.
Namba, Kei, Kazuhiko Shien, Yuta Takahashi, et al.. (2018). Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer Cells. Molecular Cancer Research. 17(2). 499–507. 71 indexed citations
9.
Sato, Hiroki, Hiromasa Yamamoto, Masakiyo Sakaguchi, et al.. (2018). Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer. Cancer Science. 109(10). 3183–3196. 55 indexed citations
10.
Takahashi, Yuta, Kazuhiko Shien, Shuta Tomida, et al.. (2018). Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis. Cancer Science. 109(11). 3634–3642. 21 indexed citations
11.
Kurihara, Eisuke, et al.. (1991). Hepatocellular carcinoma with tumor thrombus extending into the right atrium: report of a successful resection with the use of cardiopulmonary bypass.. PubMed. 109(2). 214–9. 55 indexed citations
12.
Kikuchi, Kenji, et al.. (1987). [Evaluation of tumor marker CA15-3 in breast cancer].. PubMed. 14(11). 3095–100. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026